ReviewNature chemistry2015
Recent advances in the molecular design of synthetic vaccines.
Review in Nature chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 115 citations in OpenAlex.
- Synthetic Ligands of Myeloid C-Type Lectin Receptors.Chembiochem : a European journal of chemical biology · 2026Review
- Review
- Development of a Self-Adjuvanting Influenza Peptide-Glycolipid Conjugate Inducing CD8Chembiochem : a European journal of chemical biology · 2026Article
- Soluble multi-epitope protein vaccination leverages antigen availability to drive CD8Frontiers in immunology · 2026Article
- Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia.Vaccines · 2025Article
- Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines · 2025Review
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Using immunoinformatics and bioinformatics approach to design novel and effective rational in-silico vaccine against humanIn silico pharmacology · 2025Article
- Applications of genetic code expansion technology in eukaryotes.Protein & cell · 2024Review
- B and T Cell Epitopes of the Incursionary Foot-and-Mouth Disease Virus Serotype SAT2 for Vaccine Development.Viruses · 2023Review
- New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants.Journal of medicinal chemistry · 2023Article
- A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™.Frontiers in cardiovascular medicine · 2023Review
- Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1.Vaccines · 2022Article
- Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.Molecules (Basel, Switzerland) · 2022Review
- Harnessing galactose oxidase in the development of a chemoenzymatic platform for glycoconjugate vaccine design.The Journal of biological chemistry · 2022Article
- Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development.Chemical science · 2021Article
- Streamlining Peptide Mapping LC-MS Approach for Studying Fusion Peptide-Conjugated Vaccine Immunogens.Journal of the American Society for Mass Spectrometry · 2021Article
- Simultaneous Evaluation of a Vaccine Component Microheterogeneity and Conformational Integrity Using Native Mass Spectrometry and Limited Charge Reduction.Journal of the American Society for Mass Spectrometry · 2021Article
- Replacing the Rhamnose-Xylose Moiety of QS-21 with Simpler Terminal Disaccharide Units Attenuates Adjuvant Activity in Truncated Saponin Variants.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- A biomimetic antitumor nanovaccine based on biocompatible calcium pyrophosphate and tumor cell membrane antigens.Asian journal of pharmaceutical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines have typically been prepared using whole organisms. These are normally either attenuated bacteria or viruses that are live but have been altered to reduce their virulence, or pathogens that have been inactivated and effectively killed through exposure to heat or formaldehyde. However, using whole organisms to elicit an immune response introduces the potential for infections arising from a reversion to a virulent form in live pathogens, unproductive reactions to vaccine components or batch-to-batch variability. Synthetic vaccines, in which a molecular antigen is conjugated to a carrier protein, offer the opportunity to circumvent these problems. This Perspective will highlight the progress that has been achieved in developing synthetic vaccines using a variety of molecular antigens. In particular, the different approaches used to develop conjugate vaccines using peptide/proteins, carbohydrates and other small molecule haptens as antigens are compared.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.